GRF(1-29) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
=== Legal status === In Russia bupropion is banned as a narcotic drug, due to it being a derivative of methcathinone. In Australia, France, and the UK, smoking cessation is the only licensed use of bupropion, and no generics are marketed.
== Reported incidents == In 2017 the BBC reported a case in which a male hedgehog was "almost twice its natural size, literally blown up like a beach ball with incredibly taut skin". The head vet at Stapeley's Wildlife Hospital, Bev Panto, said, "In my career I have seen three or four of these cases and they are very strange every time and quite shocking [...] When you first see them they appear to be very big hedgehogs but when you pick them up they feel so light because they are mostly air". She added that the condition was unique to hedgehogs because they have significant space under their skin as a result of their ability to curl up. A similar case had been reported in 2013. In 2024, a hedgehog that was spotted by a passing bus passenger "swollen to the size of a football" was successfully deflated by rescuers in Gloucestershire.
Some imidazole derivatives show effects on insects, for example sulconazole nitrate exhibits a strong anti-feeding effect on the keratin-digesting Australian carpet beetle larvae Anthrenocerus australis, as does econazole nitrate with the common clothes moth Tineola bisselliella.
=== Fraud convictions === From 2017 to 2019, Cochran operated a $2.5 million Ponzi scheme, defrauding investors under the guise of a government contracting business. She persuaded at least 11 individuals to invest in her companies, Technology Management Solutions and Tactical Solutions Group, by falsely claiming she had lucrative government contracts. Instead of investing the funds, Cochran used the money for personal expenses, including purchasing real estate, jewelry, and a 1965 Shelby Cobra. She also used funds from new investors to pay partial returns to earlier investors, a hallmark of Ponzi schemes. One investor alone lost over $500,000 due to her fraudulent activities. Cochran pleaded guilty to wire fraud and money laundering on September 21, 2020, and was sentenced to 135 months in federal prison. She was also ordered to pay $2.5 million in restitution and forfeit assets obtained through her scheme.
=== Multilateral Surveillance === The OECD conducts multilateral surveillance as part of its economic monitoring and policy co-ordination activities among member countries. This function has developed through regular peer reviews, comparative analysis, and policy assessments carried out within the framework of the Organisation's committees and its Economics Department.
Sources: en.wikipedia.org
Balances for accurately measuring materials. Laboratory glassware, such as burettes and pipettes, for performing titrations. Colorimeters for solution tests which apply the Beer–Lambert law. Spectrophotometer to measure the concentrations of the key parameter nitrate and other nutrients, such as phosphate, sulfate or iron. Containers for growing and storing the plants. Using chemical equipment for hydroponic solutions can be beneficial to growers of any background because nutrient solutions are often reusable. Because nutrient solutions are virtually never completely depleted, and should never be due to the unacceptably low osmotic pressure that would result, re-fortification of old solutions with new nutrients can save growers money and can control point source pollution, a common source for the eutrophication of nearby lakes and streams.
Alternative pathway of endogenous antigen processing and presentation over MHC-II molecules exists in medullary thymic epithelial cells (mTEC) via the process of autophagy. It is important for the process of central tolerance of T cells in particular the negative selection of autoreactive clones. Random gene expression of the whole genome is achieved via the action of AIRE and a self-digestion of the expressed molecules presented on both MHC-I and MHC-II molecules.
The National Administrative Department of Statistics (DANE) does not collect religious statistics, and accurate reports are difficult to obtain. However, based on various studies and a survey, about 90% of the population adheres to Christianity, the majority of which (70.9%–79%) are Roman Catholic, while a significant minority (16.7%) adhere to Protestantism (primarily Evangelicalism). Some 4.7% of the population is atheist or agnostic, while 3.5% claim to believe in God but do not follow a specific religion. 1.8% of Colombians adhere to Jehovah's Witnesses and Adventism and less than 1% adhere to other religions, such as the Baháʼí Faith, Islam, Judaism, Buddhism, Mormonism, Hinduism, Indigenous religions, Hare Krishna movement, Rastafari movement, Eastern Orthodoxy, and spiritual studies. The remaining people either did not respond or replied that they did not know. In addition to the above statistics, 35.9% of Colombians reported that they did not practice their faith actively. 1,519,562 people in Colombia, or around 3% of the population reported following an Indigenous religion. While Colombia remains a mostly Roman Catholic country by baptism numbers, the 1991 Colombian constitution guarantees freedom of religion and all religious faiths and churches are equally free before the law.
ARGX-115 is a first-in-class immunotherapy targeting GARP (glycoprotein A repetitions predominant), a membrane protein believed to enhance the immunosuppressive effects of T cells. The company also announced a deal to co-develop/commercialize at least one of CytomX Probody's conjugates against CD71 (transferrin receptor 1). In June 2019, AbbVie announced it would acquire Irish-based Allergan plc for about $63 billion; however the transaction was not structured as a tax inversion; AbbVie remained legally domiciled in the U.S. for tax purposes. To gain FTC approval, the company divested Allergan's late-stage gastrointestinal candidate brazikumab to AstraZeneca as well as two pancreatic replacement enzymes, Zenpep and Viokace, to Nestlé. In July 2019, the company announced it would acquire Mavupharma, boosting its cancer drug pipeline. In March 2020, during the COVID-19 pandemic, AbbVie announced plans to evaluate the Kaletra/Aluvia HIV medicine as possible COVID-19 treatment. The company entered into various partnerships with health authorities in different countries to investigate the efficacy of the medication. However, the first non-blinded, randomized trial found the drug not useful to treat severe COVID-19. The Israeli government announced that it would force AbbVie to license its patents for Kaletra, the brand name of lopinavir/ritonavir, a fixed dose combination medication for the treatment and prevention of HIV/AIDS which was also thought to have some applicability to fighting COVID-19.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.